Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Trends reported in vaccination coverage for adolescents for 2025 (opens in a new tab)

medicalxpress.com · 2026-09-11

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 8 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Supported

Every claim holds up. All eight claims match what the study reports.

  • 8 supported
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8SupportedTdap and MenACWY vaccination coverage for adolescents remained around 90% in 2025.View evidenceHide evidence

As statedaround 90%

Why this verdict

The abstract-level profile states that in 2025 coverage with at least one dose of Tdap and at least one dose of MenACWY remained approximately 90%. The headline framing does not outrun the body on this point.

1

Study evidence

Coverage with ≥1 dose of Tdap and ≥1 dose of MenACWY decreased in 2025 compared with 2024 but remained approximately 90%.Approximately 90% for both Tdap ≥1 dose and MenACWY ≥1 dose in 2025; described as decreased versus 2024 (magnitude not specified in abstract).

“Data from the 2025 National Immunization Survey-Teen for 18,692 adolescents aged 13-17 years were analyzed to assess trends in adolescent vaccination coverage.”
Claim 2 of 8SupportedHPV vaccination did not increase for the fourth consecutive year in 2025.View evidenceHide evidence

As statedfourth consecutive year

Why this verdict

The profile explicitly reports that HPV vaccination coverage, for both at least one dose and up-to-date series, did not increase for the fourth consecutive year.

1

Study evidence

Coverage with ≥1 dose of Tdap and ≥1 dose of MenACWY decreased in 2025 compared with 2024 but remained approximately 90%.Approximately 90% for both Tdap ≥1 dose and MenACWY ≥1 dose in 2025; described as decreased versus 2024 (magnitude not specified in abstract).

“Data from the 2025 National Immunization Survey-Teen for 18,692 adolescents aged 13-17 years were analyzed to assess trends in adolescent vaccination coverage.”
Claim 3 of 8SupportedCassandra Pingali and colleagues analyzed 2025 National Immunization Survey-Teen data from 18,692 adolescents ages 13 to 17 years to examine trends in vaccination coverage.View evidenceHide evidence

As stated18,692 adolescents ages 13–17 years

Why this verdict

The profile supports the scientific content of the claim: 2025 NIS-Teen data from 18,692 adolescents aged 13–17 years were analyzed to assess trends in adolescent vaccination coverage. The supplied profile does not independently detail the author list, but the dataset, sample, ages, and analytic purpose are supported.

1

Study evidence

Coverage with ≥1 dose of Tdap and ≥1 dose of MenACWY decreased in 2025 compared with 2024 but remained approximately 90%.Approximately 90% for both Tdap ≥1 dose and MenACWY ≥1 dose in 2025; described as decreased versus 2024 (magnitude not specified in abstract).

“Data from the 2025 National Immunization Survey-Teen for 18,692 adolescents aged 13-17 years were analyzed to assess trends in adolescent vaccination coverage.”
Claim 4 of 8SupportedCompared with 2024, coverage in 2025 with one or more doses of Tdap and one or more doses of MenACWY decreased but remained around 90%.View evidenceHide evidence

As statedaround 90%

Why this verdict

The profile states that compared with 2024, coverage with at least one dose of Tdap and at least one dose of MenACWY decreased but remained approximately 90% in 2025.

1

Study evidence

Coverage with ≥1 dose of Tdap and ≥1 dose of MenACWY decreased in 2025 compared with 2024 but remained approximately 90%.Approximately 90% for both Tdap ≥1 dose and MenACWY ≥1 dose in 2025; described as decreased versus 2024 (magnitude not specified in abstract).

“Data from the 2025 National Immunization Survey-Teen for 18,692 adolescents aged 13-17 years were analyzed to assess trends in adolescent vaccination coverage.”
Claim 5 of 8SupportedHPV vaccine coverage, measured both as one or more doses and as up to date with the series, did not increase and remained lower than Tdap and MenACWY coverage.View evidenceHide evidence

Why this verdict

The profile states that HPV vaccination coverage, measured as both at least one dose and up to date with the series, did not increase for the fourth consecutive year and remained lower than Tdap and MenACWY coverage.

1

Study evidence

Coverage with ≥1 dose of Tdap and ≥1 dose of MenACWY decreased in 2025 compared with 2024 but remained approximately 90%.Approximately 90% for both Tdap ≥1 dose and MenACWY ≥1 dose in 2025; described as decreased versus 2024 (magnitude not specified in abstract).

“Data from the 2025 National Immunization Survey-Teen for 18,692 adolescents aged 13-17 years were analyzed to assess trends in adolescent vaccination coverage.”
Claim 6 of 8SupportedCompared with adolescents in mostly urban areas, HPV vaccination coverage was 12.0 percentage points lower among adolescents living in mostly rural areas.View evidenceHide evidence

As stated12.0 percentage points lower

Why this verdict

The profile reports that HPV coverage with at least one dose was 12.0 percentage points lower among adolescents in nonmetropolitan, mostly rural areas than among those in metropolitan, mostly urban areas.

1

Study evidence

In 2025, coverage with at least one dose of HPV vaccine was 12.0 percentage points lower among adolescents living in nonmetropolitan (mostly rural) areas compared with those in metropolitan (mostly urban) areas.12.0 percentage points

“Differences in vaccination coverage between nonmetropolitan statistical areas (mostly rural) and metropolitan statistical areas (mostly urban) persisted in 2025: coverage with ≥1 dose of HPV vaccine was 12.0 percentage points lower”
Claim 7 of 8SupportedVaccination coverage varied by jurisdiction, with the largest variation seen for the HPV vaccine.View evidenceHide evidence

As statedlargest variation

Why this verdict

The profile states that vaccination coverage varied by jurisdiction and that the largest variation was observed for HPV vaccine.

1

Study evidence

In 2025, coverage with at least one dose of HPV vaccine was 12.0 percentage points lower among adolescents living in nonmetropolitan (mostly rural) areas compared with those in metropolitan (mostly urban) areas.12.0 percentage points

“Differences in vaccination coverage between nonmetropolitan statistical areas (mostly rural) and metropolitan statistical areas (mostly urban) persisted in 2025: coverage with ≥1 dose of HPV vaccine was 12.0 percentage points lower”
Claim 8 of 8SupportedThe authors said continued efforts are needed to increase adolescent vaccination coverage with recommended vaccines and reduce geographic differences in coverage, particularly for HPV vaccine.View evidenceHide evidence

Why this verdict

The profile supports that the paper offered public health interpretation and practice-oriented recommendations in response to stagnant HPV coverage and geographic disparities. It does not establish that any recommended efforts were tested for effectiveness, but the story frames this as the authors’ recommendation rather than as an evaluated intervention effect.

1

Study evidence

Clinicians should review adolescent vaccination records, discuss recommended vaccines with families, and administer all recommended vaccines that are due during all clinical encounters to help ensure adolescents are up to date.

“To ensure that adolescents are up to date, providers can review adolescent vaccination records, discuss recommended vaccines with families, and during all clinical encounters, administer all recommended vaccines that are due.”
2

Study evidence

In 2025, coverage with at least one dose of HPV vaccine was 12.0 percentage points lower among adolescents living in nonmetropolitan (mostly rural) areas compared with those in metropolitan (mostly urban) areas.12.0 percentage points

“Differences in vaccination coverage between nonmetropolitan statistical areas (mostly rural) and metropolitan statistical areas (mostly urban) persisted in 2025: coverage with ≥1 dose of HPV vaccine was 12.0 percentage points lower”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Practice-oriented interpretation: providers can review adolescent vaccination records, discuss recommended vaccines with families, and administer due vaccines during clinical encounters.

    The story includes a broad statement that continued efforts are needed, but it does not reflect the profile’s specific provider-facing actions.

    From Narrative interpretation

  • For subgroup and jurisdictional findings, the abstract reports the 12.0 percentage-point rural–urban HPV gap and largest HPV jurisdictional variation but does not provide uncertainty measures or jurisdiction-specific ranges.

    The story reports the disparity and variation findings without acknowledging that the abstract-level evidence lacks confidence intervals, statistical significance information, or quantified jurisdictional ranges.

    From Secondary analysis of 2025 NIS-Teen (cross-sectional survey, subgroup and jurisdictional comparisons)

5 things the story did carry across
  • 2025 NIS-Teen secondary analysis of adolescents aged 13–17 years, with n=18,692, used to estimate national adolescent vaccination coverage and trends.
  • Tdap and MenACWY coverage decreased compared with 2024 but remained approximately 90% in 2025.
  • HPV vaccination coverage did not increase for a fourth consecutive year and remained lower than Tdap and MenACWY coverage.
  • Rural–urban disparity in HPV coverage: at least one HPV dose was 12.0 percentage points lower in mostly rural/nonmetropolitan areas than in mostly urban/metropolitan areas.
  • Vaccination coverage varied by jurisdiction, with the largest variation observed for HPV vaccine.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate 2025 U.S. adolescent (ages 13–17 years) vaccination coverage and trends for Tdap, MenACWY, and HPV using National Immunization Survey-Teen data (including comparisons with 2024).Secondary analysis of NIS-Teen (survey-weighted coverage estimation, year-to-year trend comparison)Expand

In plain English

Secondary analysis of 2025 National Immunization Survey-Teen (NIS-Teen) data (n=18,692) to estimate national vaccination coverage and year-to-year trends (2024 vs 2025) for adolescent vaccines Tdap, MenACWY, and HPV. Findings: ≥1-dose coverage for Tdap and MenACWY remained approximately 90% in 2025 but decreased relative to 2024; HPV vaccination coverage (both ≥1 dose and up-to-date series) did not increase for a fourth consecutive year and remained lower than Tdap and MenACWY. Coverage varied by jurisdiction, with the largest variation for HPV, and HPV ≥1-dose coverage was 12.0 percentage points lower in mostly rural (nonmetropolitan) areas than in mostly urban (metropolitan) areas. Recommendations for providers to review records and administer due vaccines during all clinical encounters are stated.

Key findings

  • Coverage with ≥1 dose of Tdap and ≥1 dose of MenACWY decreased in 2025 compared with 2024 but remained approximately 90%.Approximately 90% for both Tdap ≥1 dose and MenACWY ≥1 dose in 2025; described as decreased versus 2024 (magnitude not specified in abstract).
  • HPV vaccination coverage (both ≥1 dose and up-to-date series) did not increase in 2025, marking the fourth consecutive year without an increase, and remained lower than coverage for Tdap and MenACWY.No increase reported for fourth consecutive year; specific coverage percentages not provided in abstract.
“Data from the 2025 National Immunization Survey-Teen for 18,692 adolescents aged 13-17 years were analyzed to assess trends in adolescent vaccination coverage.”
What this piece can’t prove
  • Abstract does not present confidence intervals, p-values, response rates, or detailed analytic/weighting procedures for the NIS-Teen estimates.

1 further detail could not be confirmed from the summary.

2secondary dataCharacterize disparities in vaccination coverage by geography (metropolitan vs nonmetropolitan statistical areas) and describe variation by jurisdiction, highlighting gaps especially for HPV vaccination.Secondary analysis of 2025 NIS-Teen (cross-sectional survey, subgroup and jurisdictional comparisons)Expand

In plain English

Secondary analysis of 2025 National Immunization Survey-Teen (NIS-Teen) reporting persistent rural–urban disparities and jurisdictional variation in adolescent vaccination coverage; coverage with at least one HPV dose was 12.0 percentage points lower in nonmetropolitan (mostly rural) areas compared with metropolitan (mostly urban) areas, and HPV coverage showed the largest variation across jurisdictions.

Key findings

  • In 2025, coverage with at least one dose of HPV vaccine was 12.0 percentage points lower among adolescents living in nonmetropolitan (mostly rural) areas compared with those in metropolitan (mostly urban) areas.12.0 percentage points
  • Vaccination coverage varied by jurisdiction, with the largest variation observed for HPV vaccine.
“Differences in vaccination coverage between nonmetropolitan statistical areas (mostly rural) and metropolitan statistical areas (mostly urban) persisted in 2025: coverage with ≥1 dose of HPV vaccine was 12.0 percentage points lower”
3otherProvide public health interpretation and practice implications (e.g., provider actions to improve adolescents being up to date).Narrative interpretationExpand

In plain English

The report provides practice-oriented recommendations for clinicians to increase adolescent vaccine coverage: review adolescent vaccination records, discuss recommended vaccines with families, and administer all recommended vaccines that are due during all clinical encounters. These recommendations are presented as interpretation of 2025 NIS-Teen surveillance findings showing stagnant HPV coverage and persistent rural–urban disparities.

Key findings

  • Clinicians should review adolescent vaccination records, discuss recommended vaccines with families, and administer all recommended vaccines that are due during all clinical encounters to help ensure adolescents are up to date.
“To ensure that adolescents are up to date, providers can review adolescent vaccination records, discuss recommended vaccines with families, and during all clinical encounters, administer all recommended vaccines that are due.”
What this piece can’t prove
  • Recommendations are interpretive and practice-oriented rather than results of an intervention study.
  • The report does not evaluate the effectiveness or implementation feasibility of the recommended provider actions.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

And 32 more candidates considered.